From how I see this. Easton is a pharma company with products coming to market soon. Someone asked on this board "why does someone need to partner with EAPH to sell MJ they can just do it on their own". EAPH is not looking to sell MJ they need a grower/supplier for the Hemp products they have in the pipeline. The agreement with the B.C. Company will happen why not? If I own a MJ facilities and have a pharma co. that came to me and said hey, we need you to supply us with your product and we will buy X amount every month. I would be happy as hell if I was the MJ supplier, would you be?.. EAPH needs an ongoing guaranteed supplier for its own line of HEMP based products. I would think the MJ supplier would be the one that is getting the sweet deal. They don't have to deal with individual sales and they get guaranteed product sales every week or month to EAPH. This way they know when they plant its already sold no risk. All this big news that people are waiting for is just an agreement on pricing and quantity with a guarantee ongoing purchase legal agreement from EAPH. I think this is a great good long term play. If the news is taking longer then 10 days its because, EAPH being the buyer, is trying to get better pricing and terms. Read the news again below I know most have seen it but it backs up my stance that this is a good buy at these prices and will rise over time. Patience people, patience and we will be rewarded
Easton Pharmaceuticals Inc. (OTC: EAPH) a specialty pharmaceutical company that owns, designs, develops, and markets an array of topically-delivered drugs and therapeutic / cosmetic healthcare products, today announces it has received a proposal from an accredited investor to increase its financing from the current $1,000,000 per year it is eligible to currently receive and has been receiving, to $5,000,000 per year by filing a Regulation A Offering Statement with the SEC.
Easton Pharmaceuticals has for the past 6 months been financed from accredited investors through regulation D offerings. The same investors have recently notified the company of their intent to pay for legal fees to allow Easton Pharmaceuticals file a Regulation A Offering Statement with the Securities and Exchange Commission, allowing the company to be financed up to an amount of $5,000,000 per year on a best efforts basis, an increase from the current $1,000,000 per year presently allowed under regulation D. Financing of such an amount would allow the company to meet most if not all of its current business initiatives which includes; 1) to complete the approval process of Viorra in Mexico and other latin countries, manufacture and mass market its "Viorra" product, designed to help treat FSAD throughout North America and other international countries; 2) to start FDA clinical trials for Its cancer drug "XILIVE", which the company currently maintains a minority ownership in, but is in discussions to increase; 3) expand on its medical marijuana initiatives, and; 4) to bring other products in its portfolio to market including recently added HEMP based products to compliment its medical marijuana initiatives. Easton is presently reviewing the financing proposal and other options and expects to reach a decision within the next few weeks.
In other developments, Easton Pharmaceuticals has quickly made the decision to move forwarding with submitting a formal term-sheet towards finalizing and executing a partnership / finance agreement after being satisfied with its due diligence process towards its recently executed LOI / NDA with a private B.C. company who were recently granted a national medical marijuana license. The company will be forwarding what it believes will be a fair and equitable agreement to both sides as management believes delving into the medical marijuana sector at this point in time provides a quick avenue for the company to reach its goals of attaining positive revenues with good growth prospects. Although Easton is not disclosing any names at this point so not to compromise negotiations, it can reveal that this company is one of only a small handful of companies who have thus far been approved and granted a federal medical marijuana growers / distributors license for the entire country of Canada which is similar in size to the state of California. This company is not only considered throughout the industry as possessing leading expertise and knowledge, but also maintaining one of the premium facilities throughout Canada for growing Cannabis. Easton management and consultants are impressed with this companies business model and revenue projections that show exponential yearly increases in revenue, which the company believes are very realistic and attainable. Additional updates to be disclosed as they become available, however it is vital that both companies come to a quick resolution and decision.
In other developments, Easton Pharmaceuticals has entered into discussions and is close to finalizing a possible deal to dramatically increase its ownership interest in the cancer drug "XILIVE". The company presently maintains a 10 percent ownership interest in XILIVE, but is in discussions and believes its ownership interest can be increased for the most part by issuing common shares of Easton Pharmaceuticals. News towards XILIVE and additional testing / trials as a result of efforts by the current majority owners is expected to be announced sometime in the near future.
VIORRA is an over-the-counter aid for the treatment to restore and improve vaginal moisture and elasticity which is believed has have a positive effect on women's sexual desire and arousal FSAD (Female Sexual Arousal Disorder), VIORRA is a topical, daily-use product formulated with ingredients classified by the FDA as (GRAS) Generally Recognized as Safe
